

REC REF	IRAS	Name of Trial	Target Number of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/EM/0473	187884	A randomized, open-label, active-controlled, Phase II study of intravenous anetumabravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first linepla	Number Agreed	3	3	Date Agreed	31/03/2017	11	09/12/2016	11	Recruitment Finished
15/SC/0521	185323	(ABOUND) A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nabpaclitaxel (ABI-007) with epigenetic modifying therapy of CC-486, and nab-paclitaxel monotherapy as second-line treatment in subjects with advanced non	Number Agreed	4	4	Date Agreed	01/04/2017	1	05/12/2016	1	Withdrawn By Sponsor
16/LO/0361	193839	PALISADE: Peanut Allergy Oral Immunotherapy study of AR101 for Desensitisation in children and adults	Number Agreed	5	5	Date Agreed	16/11/2016	3	16/11/2016	3	Recruitment Finished
15/NW/0698	183781	Regain - TITLE: A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo? compared to standard of care insulin, in basal insulin treated pati	Number Agreed	4	4	Date Agreed	07/10/2016	1	07/10/2016	1	Recruitment Finished
15/NW/0697	183760	Reach - A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo? compared to standard of care insulin for initiating basal insulin in insulin na?ve patien	Range Agreed	4	5	Date Agreed	07/10/2016	5	07/10/2016	5	Recruitment Finished
15/WA/0241	183747	Depict 2 - A multi-centre, randomised, double blind, placebo controlled, parallel group, phase 3 study to evaluate the efficacy and safety of Dapagliflozin as an add-on to insulin therapy in subjects with Type 1 diabetes mellitus - study two	Number Agreed	4	4	Date Agreed	19/12/2016	2	19/12/2016	2	Recruitment Finished
15/SC/0115	167694	Harmony - A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus.	Range Agreed	8	10	Date Agreed	31/12/2016	6	23/11/2016	6	Recruitment Finished
15/EE/0130	170557	A randomised, open-label, multicentre study of liposomal amikacin for inhalation (LAI) in adult patients with nontuberculous mycobacterial (NTM) lung infections caused by mycobacterium avium complex (MAC) that are refractory to treatment	Number Agreed	1	1	Date Agreed	04/11/2016	0	04/11/2016	0	Recruitment Finished
15/WM/0331	184594	Heart Mate 3	Range Agreed	15	20	Date Agreed	30/01/2017	20	30/01/2017	20	Recruitment Finished

15/EM/0309	184678	CLEARCUT VR475	Number Agreed	3	3	Date Agreed	28/02/2017	3	06/03/2017	3	Recruitment Finished
15/SW/0248	186033	Vertex VX14-661-110	Number Agreed	8	8	Date Agreed	25/10/2016	8	15/11/2016	8	Recruitment Finished
16/SC/0018	191267	EMPIRE CTX4430	Number Agreed	4	4	Date Agreed	31/03/2017	4	31/03/2017	4	Recruitment Finished
15/NW/0255	163780	TANGO II	Number Agreed	4	4	Date Agreed	31/12/2017	1	08/02/2017	1	Withdrawn By Sponsor
15/LO/1500	187068	BI 1199.229	Number Agreed	4	4	Date Agreed	31/01/2017	6	14/03/2017	6	Recruitment Finished
16/NW/0787	216022	ALBATROSS	Number Agreed	2	2	Date Agreed	15/06/2017	4	22/06/2017	4	Recruitment Finished
15/NW/0747	186601	Boehringer Biosimilar	Number Agreed	6	6	Date Agreed	02/02/2017	0	02/02/2017	0	Recruitment Finished
16/SC/0341	204761	EZH-203	Range Agreed	4	5	Date Agreed	31/10/2017	1	17/05/2017	1	Withdrawn By Sponsor
16/LO/0793	203066	BI 1199.227	Number Agreed	4	4	Date Agreed	15/03/2017	13	15/03/2017	13	Recruitment Finished
15/NW/0821	191169	Oricol	Number Agreed	20	20	Date Agreed	31/07/2017	30	21/09/2017	30	Recruitment Finished
13/EE/0326	137999	Revacept	Range Agreed	64	80	Date Agreed	30/05/2017	19	30/05/2017	19	Recruitment Finished